Abeona Therapeutics Inc.

DB:PCJ Stock Report

Market Cap: €250.3m

Abeona Therapeutics Valuation

Is PCJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PCJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PCJ (€5.4) is trading below our estimate of fair value (€308.07)

Significantly Below Fair Value: PCJ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCJ?

Key metric: As PCJ is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PCJ. This is calculated by dividing PCJ's market cap by their current book value.
What is PCJ's PB Ratio?
PB Ratio5.7x
BookUS$45.77m
Market CapUS$260.69m

Price to Book Ratio vs Peers

How does PCJ's PB Ratio compare to its peers?

The above table shows the PB ratio for PCJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
FYB Formycon
1.4x31.5%€827.2m
MDG1 Medigene
1.2x-4.1%€22.6m
BIO3 Biotest
2x29.3%€1.4b
PCJ Abeona Therapeutics
5.7x62.9%€260.7m

Price-To-Book vs Peers: PCJ is expensive based on its Price-To-Book Ratio (5.7x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does PCJ's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
PCJ 5.7xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PCJ is expensive based on its Price-To-Book Ratio (5.7x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is PCJ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCJ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PCJ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PCJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.40
€15.81
+192.8%
25.5%€19.82€8.97n/a6
Nov ’25€5.85
€14.45
+147.0%
28.4%€19.06€6.81n/a6
Oct ’25€5.50
€14.45
+162.7%
28.4%€19.06€6.81n/a6
Sep ’25€4.90
€14.45
+194.9%
28.4%€19.06€6.81n/a6
Aug ’25€4.44
€15.22
+242.8%
29.7%€19.47€6.95n/a6
Jul ’25€3.86
€15.46
+300.6%
31.7%€19.44€6.94n/a5
Jun ’25€3.66
€15.46
+322.5%
31.7%€19.44€6.94n/a5
May ’25€3.12
€18.18
+482.6%
53.5%€33.56€7.46n/a4
Apr ’25€6.61
€19.32
+192.3%
43.4%€33.12€11.04n/a4
Mar ’25€6.23
€19.78
+217.5%
46.2%€34.96€11.04n/a4
Feb ’25€3.68
€19.78
+438.1%
46.2%€34.96€11.04n/a4
Jan ’25€4.53
€19.60
+332.6%
47.9%€35.04€10.14n/a4
Dec ’24€4.30
€19.60
+356.0%
47.9%€35.04€10.14n/a4
Nov ’24€3.53
€19.40
+450.1%
53.6%€35.96€7.57€5.854
Oct ’24€3.63
€19.40
+434.6%
53.6%€35.96€7.57€5.504
Sep ’24€3.99
€18.77
+370.2%
53.6%€34.80€7.33€4.904
Aug ’24€3.03
€19.15
+531.1%
47.6%€33.84€8.91€4.444
Jul ’24€3.63
€19.70
+442.7%
47.6%€34.82€9.16€3.864
Jun ’24€2.82
€21.08
+647.5%
51.1%€35.34€9.30€3.663
May ’24€2.77
€20.54
+641.6%
51.1%€34.44€9.06€3.123
Apr ’24€2.54
€26.87
+957.8%
31.0%€35.21€18.53€6.612
Mar ’24€2.12
€26.76
+1,162.5%
31.0%€35.07€18.46€6.232
Feb ’24€2.26
€26.76
+1,084.3%
31.0%€35.07€18.46€3.682
Jan ’24€2.58
€20.08
+678.2%
61.4%€35.76€5.65€4.533
Dec ’23€3.76
€20.64
+448.9%
61.4%€36.77€5.81€4.303
Nov ’23€4.50
€15.87
+252.6%
48.4%€22.28€5.06€3.533

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$707.40

7D

-0.9%

1Y

-3.6%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

1.3%

1Y

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%